TY - JOUR
T1 - Antiangiogenic mechanisms of simvastatin in retinal endothelial cells
AU - Hata, Yasuaki
AU - Miura, Muneki
AU - Asato, Ryo
AU - Kita, Takeshi
AU - Oba, Kumiyo
AU - Kawahara, Shuhei
AU - Arita, Ryoichi
AU - Kohno, Ri Ichiro
AU - Nakao, Shintaro
AU - Ishibashi, Tatsuro
N1 - Funding Information:
Acknowledgments We acknowledge David Goodman (Pharmas-cience), Waichiro Katsuda, Tomoko Saeki, and Noriyuki Yoshida (Aqumen Biopharmaceuticals, K.K.) for their excellent help. The study was supported in part by grants from the Ministry of Education, Science, Sports and Culture, Japan (Grant-in-Aid for Scientific Research #21592233).
PY - 2010
Y1 - 2010
N2 - Background: While statins have an anti-angiogenic property, their underlying mechanisms are not fully understood. We investigated intracellular mechanisms of simvastatin-mediated reduction in VEGF-induced signalings. Methods: The effects of simvastatin on cell proliferation and viability were evaluated by [3H]-thymidine incorporation in retinal endothelial cells (RECs) and cell counting. The impact of simvastatin on VEGF-induced phosphorylation of p44/42 mitogen-activated protein (MAP) kinase, myosin light chain (MLC), and VEGF-receptor (VEGFR) 2 were examined by Western blotting. Involvement of the mevalonate pathway in VEGF-induced signaling was also examined. Results: Simvastatin (1 and 10 μM) suppressed VEGF-induced RECs proliferation in a concentration-dependent manner, without affecting cell viability. Simvastatin significantly inhibited VEGF-induced phosphorylation of VEGFR2 and its downstream mediators, p44/42 MAP kinase and MLC. Mevalonate completely reversed VEGF-induced VEGFR2 phosphorylation, but only partially reversed the phosphorylation of p44/42 MAP kinase and MLC. Conclusion: These data indicate that simvastatin exerts its anti-angiogenic effects through the reduction of VEGFR2 phosphorylation in RECs at least in part. However, there seems to be both mevalonate-dependent and independent pathway in simvastatin's anti-angiogenic property.
AB - Background: While statins have an anti-angiogenic property, their underlying mechanisms are not fully understood. We investigated intracellular mechanisms of simvastatin-mediated reduction in VEGF-induced signalings. Methods: The effects of simvastatin on cell proliferation and viability were evaluated by [3H]-thymidine incorporation in retinal endothelial cells (RECs) and cell counting. The impact of simvastatin on VEGF-induced phosphorylation of p44/42 mitogen-activated protein (MAP) kinase, myosin light chain (MLC), and VEGF-receptor (VEGFR) 2 were examined by Western blotting. Involvement of the mevalonate pathway in VEGF-induced signaling was also examined. Results: Simvastatin (1 and 10 μM) suppressed VEGF-induced RECs proliferation in a concentration-dependent manner, without affecting cell viability. Simvastatin significantly inhibited VEGF-induced phosphorylation of VEGFR2 and its downstream mediators, p44/42 MAP kinase and MLC. Mevalonate completely reversed VEGF-induced VEGFR2 phosphorylation, but only partially reversed the phosphorylation of p44/42 MAP kinase and MLC. Conclusion: These data indicate that simvastatin exerts its anti-angiogenic effects through the reduction of VEGFR2 phosphorylation in RECs at least in part. However, there seems to be both mevalonate-dependent and independent pathway in simvastatin's anti-angiogenic property.
UR - http://www.scopus.com/inward/record.url?scp=77952083757&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952083757&partnerID=8YFLogxK
U2 - 10.1007/s00417-009-1282-4
DO - 10.1007/s00417-009-1282-4
M3 - Article
C2 - 20155363
AN - SCOPUS:77952083757
SN - 0721-832X
VL - 248
SP - 667
EP - 673
JO - Graefe's Archive for Clinical and Experimental Ophthalmology
JF - Graefe's Archive for Clinical and Experimental Ophthalmology
IS - 5
ER -